Company Number
1
ASE Corporate Eyecare Limited
Corporate directory
31 December 2025
|
Directors |
L Hodges |
|
|
M Lo Duca |
||
|
C A F Jonsson |
|
Company number |
03425183 |
|
Registered office |
Unit 14 |
|
|
Quarry Farm |
||
|
Bodiam |
||
|
East Sussex |
||
|
TN32 5RA |
|
Auditor |
|
|
|
The Paragon |
||
|
Counterslip |
||
|
Bristol |
||
|
BS1 6BX |
2
ASE Corporate Eyecare Limited
Directors' report
31 December 2025
The directors present their annual report on the affairs of ASE Corporate Eyecare Limited, together with the audited financial statements, for the year ended
These are the published financial statements of the company prepared in accordance with Financial Reporting Standard 101, ‘Reduced Disclosure Framework’ (FRS 101) and in accordance with the requirements of the Companies Act 2006.
Principal activities
Results and dividends
The profit for the year, after taxation, amounted to £884,991 (2024: £280,785)
During the year a dividend of £3 million was paid (2024: Nil). Further details are included in note 10.
Directors
The following persons were directors of the company during the whole of the financial year and up to the date of this report, unless otherwise stated:
|
|
|
|
|
|
Qualifying third party indemnity provisions
The company has made qualifying third party indemnity provisions for the benefit of its directors which were made during the year and remain in force at the date of this report. No claim or notice of claim in respect of these indemnities has been received in the year.
Business review
The profit for the company after providing for income tax amounted to £884,991 (31 December 2024: £280,785).
The Company delivered a strong financial and operational performance during the year ended 31 December 2025, successfully achieving its approved financial budget while continuing to build on the momentum established in previous years. Revenue increased by 19.7% compared with the prior year, driven by continued demand for the Company's corporate eyecare solutions, growth within existing customer relationships and the successful acquisition of new business.
During the year, the Company continued to strengthen its position within the UK corporate eyecare market by expanding its product offering and investing in service delivery. The business remained focused on delivering high-quality DSE compliance solutions while broadening its portfolio to meet the evolving needs of employers and strategic partners.
Operationally, significant progress was made in enhancing internal systems, automation and reporting capabilities. These investments have improved operational efficiency, strengthened internal controls and positioned the Company to support future growth while maintaining high levels of customer service.
3
ASE Corporate Eyecare Limited
Directors' report
31 December 2025
Business review (continued)
The Company also continued to invest in information security and governance. ISO 27001 certification was successfully maintained following three independent information security audits during the year, demonstrating the Company's ongoing commitment to data protection, regulatory compliance and operational resilience.
The business continued to strengthen its relationships with optical providers, insurers and strategic partners, supporting the continued development of both its corporate eyecare and insurance administration services. During the year, the Company also progressed the development of new product propositions designed to diversify revenue streams and enhance the value offered to customers.
The Directors are pleased with the Company's performance during 2025. The achievement of the Company’s financial objectives, together with the continued investment in technology, information security and product development, has strengthened the Company’s market position. Despite continued economic uncertainty and inflationary pressures across the UK economy, the business remained profitable, cash generative and financially resilient, providing a strong platform for continued investment and sustainable long-term growth.
Future developments
The Directors remain confident in the Company's prospects and believe it is well positioned to continue delivering sustainable growth during 2026 and beyond.
The Company's strategic priorities for the coming year include:
Product Development
Continuing the development and launch of new products and services, including enhanced employee protection solutions and complementary wellbeing offerings, to meet evolving customer requirements and diversify revenue streams.
Technology and Operational Excellence
Continuing investment in the Company's technology platform to improve automation, enhance customer experience, strengthen reporting capabilities and support increased transaction volumes while maintaining robust information security standards.
Market Expansion
Building on established relationships with corporate clients, insurers and optical providers to increase market penetration, expand strategic partnerships and identify opportunities in adjacent markets.
Customer Experience
The Company remains committed to enhancing the customer experience through continuous innovation and digital transformation, and will continue to invest in digital capabilities and customer-focused solutions to strengthen client engagement, improve operational efficiency and support the evolving needs of employers and their employees.
Maintaining high levels of service through continued investment in operational processes, provider network management and customer support, ensuring the Company remains a trusted partner for corporate eyecare and workplace compliance services.
Continued innovation
The Directors will continue to evaluate strategic opportunities that support the Company's long-term objectives while maintaining a prudent approach to financial management and investment.
The Board believes that the Company's strong market position, experienced management team, robust financial performance and continued investment in people, technology and innovation provide a solid foundation for future growth.
4
ASE Corporate Eyecare Limited
Directors' report
31 December 2025
Going concern
The Company forms part of the EssilorLuxottica Group and, where required, relies on financial support from its parent undertaking. The Directors have received a formal letter of financial support from the parent company confirming that it will provide financial support to the Company, if required, for a period of at least twelve months from the date of signing of the financial statements of the Company for the year ending 31 December 2025.
Having considered the forecasts and the financial support available from the parent undertaking, the Directors have a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future. Accordingly, they continue to adopt the going concern basis in preparing these financial statements.
Events subsequent to the end of the financial year
The company entered into a lease that commenced on 1 January 2026 for an initial contractual term of three years. The lease includes an unconditional tenant-only break and an option exercisable by the Company after six months. A right of use asset and lease liability will be measured and recognised from the lease commencement date.
No other matter or circumstance has arisen since 31 December 2025 that has significantly affected, or may significantly affect the company's operations, the results of those operations, or the company's state of affairs in future financial years.
Directors' responsibilities statement
The directors are responsible for preparing the directors' report and the financial statements in accordance with applicable law and regulations.
Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with FRS 101 'Reduced Disclosure Framework'. Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and the profit or loss of the company for that year.
In preparing these financial statements, the directors are required to:
|
• |
select suitable accounting policies and then apply them consistently; |
|
|
• |
make judgements and accounting estimates that are reasonable and prudent; |
|
|
• |
state whether FRS 101 'Reduced Disclosure Framework' has been followed, subject to any material departures disclosed and explained in the financial statements; and |
|
|
• |
prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business. |
The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.
Disclosure of information to the auditors
5
ASE Corporate Eyecare Limited
Directors' report
31 December 2025
Auditor
Following a group tender process, Forvis Mazars LLP resigned as auditor and Ernst & Young LLP were appointed.
6
ASE Corporate Eyecare Limited
Directors' report
31 December 2025
Small company provisions
This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies' exemption. The company is exempt from preparing a strategic report under s414A as it qualifies as small.
This report is made in accordance with a resolution of directors.
On behalf of the directors
|
___________________________ |
|
|
|
Director |
|
|
7
Independent auditor's report to the members of ASE Corporate Eyecare Limited
Opinion
We have audited the financial statements of ASE Corporate Eyecare Limited for the year ended 31 December 2025 which comprise Statement of comprehensive income, Statement of financial position and Statement of Changes in Equity and the related notes 1 to 22, including material accounting policy information. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards FRS 101 “Reduced Disclosure Framework” (United Kingdom Generally Accepted Accounting Practice).
In our opinion, the financial statements:
|
• |
give a true and fair view of the company’s affairs as at 31 December 2025 and of its profit for the year then ended; |
|
|
• |
have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and |
|
|
• |
have been prepared in accordance with the requirements of the Companies Act 2006. |
Basis for opinion
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor’s responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements.
We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
Conclusions relating to going concern
In auditing the financial statements, we have concluded that the directors’ use of the going concern basis of accounting in the preparation of the financial statements is appropriate.
Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company’s ability to continue as a going concern for a period of twelve months from when the financial statements are authorised for issue.
Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report. However, because not all future events or conditions can be predicted, this statement is not a guarantee as to the company’s ability to continue as a going concern.
8
Independent auditor's report to the members of ASE Corporate Eyecare Limited
Other information
The other information comprises the information included in the annual report, other than the financial statements and our auditor’s report thereon. The directors are responsible for the other information contained within the annual report.
Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in this report, we do not express any form of assurance conclusion thereon.
Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of the other information, we are required to report that fact.
We have nothing to report in this regard.
Opinions on other matters prescribed by the Companies Act 2006
In our opinion, based on the work undertaken in the course of the audit:
|
• |
the information given in the directors’ report for the financial year for which the financial statements are prepared is consistent with the financial statements; and |
|
|
• |
the directors’ report has been prepared in accordance with applicable legal requirements. |
Matters on which we are required to report by exception
In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the directors’ report.
We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:
|
• |
adequate accounting records have not been kept or returns adequate for our audit have not been received from branches not visited by us; or |
|
|
• |
the financial statements are not in agreement with the accounting records and returns; or |
|
|
• |
certain disclosures of directors’ remuneration specified by law are not made; or |
|
|
• |
we have not received all the information and explanations we require for our audit; or |
|
|
• |
the directors were not entitled to take advantage of the small companies' exemption in preparing the directors' report and from the requirements to prepare a strategic report. |
Responsibilities of directors
As explained more fully in the directors’ responsibilities statement set out on page 5, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.
In preparing the financial statements, the directors are responsible for assessing the company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.
9
Independent auditor's report to the members of ASE Corporate Eyecare Limited
Auditor’s responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.
Explanation as to what extent the audit was considered capable of detecting irregularities, including fraud
Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect irregularities, including fraud. The risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery or intentional misrepresentations, or through collusion. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below. However, the primary responsibility for the prevention and detection of fraud rests with both those charged with governance of the entity and management.
|
• |
We obtained an understanding of the legal and regulatory frameworks that are applicable to the company and determined that the most significant are those that relate to reporting framework (FRS 101 and Companies Act 2006) and compliance with the relevant direct and indirect tax regulation in the United Kingdom. In additional, the Company has to comply with laws and regulations to its operations, including health and safety and General Data Protection Regulation (GDPR). |
|
|
• |
We understood how ASE Corporate Eyecare Limited is complying with those frameworks by making enquiries of management and those charged with governance to understand how the Company maintains and communicates its policies and procedures in these areas. We understood the controls put in place by management to reduce the opportunities for fraudulent transactions. |
|
• |
We assessed the susceptibility of the company’s financial statements to material misstatement, including how fraud might occur by including how fraud might occur through inquiries made of management together with those charged with governance, and internal team discussions. We considered the controls that the company has established to address the risks identified, or that otherwise prevent, deter and detect fraud; and how senior management monitors those controls. Where the risk was considered to be higher, we performed audit procedures to address each identified fraud risk, including the specific risk related to management override, specifically through the posting of manual revenue journals. The procedures performed included testing manual journals and meeting specific risk criteria and agreed those transactions back to source documentation. |
|
|
• |
Based on this understanding we designed our audit procedures to identify noncompliance with such laws and regulations. Our procedures involved enquiries of management, as well as journal entry testing with a focus on manual journals and journals indicating significant or unusual transactions based on our understanding of the business, verifying that material transactions are recorded in compliance with FRS 101 and where appropriate Companies Act 2006. Compliance with other operational laws and regulations was covered through our inquiry with no indication of non-compliance identified. |
A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council’s website at https://www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor’s report.
10
Independent auditor's report to the members of ASE Corporate Eyecare Limited
Use of our report
This report is made solely to the company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company’s members those matters we are required to state to them in an auditor’s report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company’s members as a body, for our audit work, for this report, or for the opinions we have formed.
for and on behalf of Ernst & Young LLP, Statutory Auditor
Bristol
Date: 1 July 2026
11
ASE Corporate Eyecare Limited
Statement of comprehensive income
For the year ended 31 December 2025
|
Note |
2025 |
2024 |
||||
|
£ |
£ |
|||||
|
Revenue |
4 |
|
|
|||
|
Cost of sales |
( |
( |
||||
|
Gross profit |
|
|
||||
|
Other income |
|
- |
||||
|
Administrative expenses |
( |
( |
||||
|
Operating profit |
5 |
|
|
|||
|
Finance income |
7 |
|
|
|||
|
Finance expense |
8 |
( |
( |
|||
|
Profit before income tax |
|
|
||||
|
Income tax credit/(charge) |
9 |
|
( |
|||
|
Profit after income tax for the year attributable to the owners of ASE Corporate Eyecare Limited |
|
|
||||
|
Other comprehensive income for the year, net of tax |
- |
- |
||||
|
Total comprehensive income for the year attributable to the owners of |
|
|
||||
All results were derived from continuing operations.
12
ASE Corporate Eyecare Limited
Statement of financial position
As at 31 December 2025
|
Note |
2025 |
2024 |
||||
|
£ |
£ |
|||||
|
Fixed assets |
||||||
|
Intangible assets |
11 |
|
|
|||
|
Property, plant and equipment |
12 |
|
|
|||
|
236,801 |
290,926 |
|||||
|
Current assets |
||||||
|
Debtors |
13 |
|
|
|||
|
|
|
|||||
|
Current liabilities |
||||||
|
Creditors |
14 |
( |
( |
|||
|
(1,364,316) |
(2,115,431) |
|||||
|
Net current assets |
|
|
||||
|
Total assets less current liabilities |
|
|
||||
|
Net assets before deferred tax liability |
1,337,803 |
3,509,651 |
||||
|
Deferred tax |
15 |
( |
( |
|||
|
Net assets |
|
|
||||
|
Equity |
||||||
|
Called up share capital |
16 |
5,000 |
5,000 |
|||
|
Capital redemption reserve |
17 |
20 |
20 |
|||
|
Share based payment reserve |
17 |
(51,329) |
- |
|||
|
Retained profits |
1,380,708 |
3,495,717 |
||||
|
Total equity |
|
|
ASE Corporate Eyecare Limited's company number is 03425183.
The financial statements were approved by the Board of Directors and signed on its behalf by:
|
___________________________ |
|
|
|
Director |
|
|
13
ASE Corporate Eyecare Limited
Statement of changes in equity
For the year ended 31 December 2025
|
Issued |
Capital redemption |
Retained |
Total equity |
|||||
|
capital |
reserve |
profits |
||||||
|
£ |
£ |
£ |
£ |
|||||
|
Balance at 1 January 2024 |
|
|
|
3,219,952 |
||||
|
Profit after income tax for the year |
- |
- |
|
|
||||
|
Total comprehensive income for the year |
- |
- |
|
280,785 |
||||
|
Balance at 31 December 2024 |
|
|
|
3,500,737 |
|
Issued |
Capital redemption |
Share based payments |
Retained |
Total equity |
||||||
|
capital |
reserve |
reserve |
profits |
|||||||
|
£ |
£ |
£ |
£ |
£ |
||||||
|
Balance at |
|
|
- |
|
3,500,737 |
|||||
|
Profit after income tax for the year |
- |
- |
- |
|
|
|||||
|
Total comprehensive income for the year |
- |
- |
- |
|
884,991 |
|||||
|
Transactions with owners in their capacity as owners: |
||||||||||
|
Share-based payments (note 21) |
- |
- |
( |
- |
(51,329) |
|||||
|
Dividends paid (note 10) |
- |
- |
- |
( |
(3,000,000) |
|||||
|
Balance at |
|
|
( |
|
1,334,399 |
14
ASE Corporate Eyecare Limited
Notes to the financial statements
31 December 2025
Note 1. General information
The principal activities of the company during the year were the provision of corporate eyecare and the administration of a vaccination contract.
The financial statements cover
Note 2. Material accounting policy information
The accounting policies that are material to the company are set out below. The accounting policies adopted are consistent with those of the previous financial year, unless otherwise stated.
New or amended Accounting Standards and Interpretations adopted
The company has adopted all of the new or amended Accounting Standards and Interpretations issued by the Financial Reporting Council ('FRC') that are mandatory for the current reporting period.
Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.
Basis of preparation
Historical cost convention
Critical accounting estimates
The preparation of the financial statements requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the company's accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the financial statements, are disclosed in note 3.
15
ASE Corporate Eyecare Limited
Notes to the financial statements
31 December 2025
Going concern
The Company forms part of the EssilorLuxottica Group and, where required, relies on financial support from its parent undertaking. The Directors have received a formal letter of financial support from the parent company confirming that it will provide financial support to the Company, if required, for a period of at least twelve months from the date of signing of the financial statements of the Company for the year ending 31 December 2025.
Having considered the forecasts and the financial support available from the parent undertaking, the Directors have a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future. Accordingly, they continue to adopt the going concern basis in preparing these financial statements.
Foreign currency translation
Foreign currency transactions
Revenue recognition
It is measured at the fair value of the consideration received or receivable, net of value added tax. Performance obligations are identified at contract inception, and the revenue is recognised once the performance obligations are satisfied. The Company generates revenue from three principal sources: 1. Voucher-Based DSE Compliance Services The Company provides Display Screen Equipment compliance services to corporate customers through access to a dedicated platform and the issuance of employee specific vouchers. The issue of a voucher gives rise to a right-to-service performance obligation for the Company. Each voucher is valid for a specified period and must be exercised within that period; otherwise, the right to receive the service expires. 2. Direct Settlement Administration Services The Company administers insured optical transactions on behalf of insurers by facilitating the settlement of claims between insurers and participating optical providers. 3. Platform and Network Management Services The Company provides technology platforms and network management services that facilitate the sale of voucher-based products and services by participating providers.
16
ASE Corporate Eyecare Limited
Notes to the financial statements
31 December 2025
Principal and Agent
Under IFRS15, the Company is a principal if it controls the promised goods or service before transferring it to the customer. The Company is an agent if its role is to arrange for another entity to provide the goods or service.
The Company acts as a principal for the following DSE services
· Access: provision of access to a dedicated platform and issuance of employee-specific voucher
· Non-Redemption income
· Redemption of employee-specific vouchers
The Company acts as an agent for the following services
· Direct Settlement Administration Services
· Platform and Network Management Services
Timing of revenue recognition
1. Voucher-Based DSE Compliance Services
Revenue is recognised
· Access and Non-Redemption income is - deferred and recognised on a straight-line basis over the contracted period, which appropriately reflects that the customers receive and consume the benefits of those performance obligations evenly throughout the contract
· Redemption of employee-specific vouchers – at the point in time when a voucher is redeemed upon provision of the underlying eye-care services and/or products, the Company considers its performance obligation in respect of that voucher to be fully satisfied
Deferred Revenue
Deferred Revenue represents consideration received or receivable for performance obligations that have not yet been satisfied.
Deferred Revenue primarily relates to DSE compliance Access services and vouchers that have been issued but for which the associated eye-care services have not yet been provided and where a right of service is present.
2. Direct Settlement Administration Services
Revenue comprises only the administration or transaction fee earned by the Company and is recognised when the settlement transaction has been completed and the Company's entitlement to consideration has been established.
3. Platform and Network Management Services
Revenue is earned as an agreed percentage of the value of completed transactions processed through the platform and is recognised when the underlying transaction has occurred and the Company's entitlement to consideration has arisen.
Current and deferred income tax
17
ASE Corporate Eyecare Limited
Notes to the financial statements
31 December 2025
|
• |
When the deferred income tax asset or liability arises from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and that, at the time of the transaction, affects neither the accounting nor taxable profits; or |
|
|
• |
When the taxable temporary difference is associated with interests in subsidiaries, associates or joint ventures, and the timing of the reversal can be controlled and it is probable that the temporary difference will not reverse in the foreseeable future. |
Cash at bank and in hand
Debtors
Property, plant and equipment
|
Fixtures and fittings |
|
|
|
Equipment |
|
18
ASE Corporate Eyecare Limited
Notes to the financial statements
31 December 2025
Intangible assets
|
• |
it is technically feasible to complete the software product so that it will be available for use; |
|
|
• |
management intends to complete the software product and use or sell it; |
|
|
• |
there is an ability to use or sell the software product; |
|
|
• |
it can be demonstrated how the software product will generate probably future economic benefits; |
|
|
• |
adequate technical, financial and other resources to complete the development and to use or sell the software product are available; and |
|
|
• |
the expenditure attributable to the software product during its development can be reliably measured. |
Other development expenditures that do not meet these criteria are recognised as an expense as incurred. Development costs previously recognised as an expense are not recognised as an asset in a subsequent period. Intangible assets amortisation is recorded in administrative expenses in the statement of comprehensive income. The database software is amortised over ten years of which four are remaining.
Impairment of non-financial assets
19
ASE Corporate Eyecare Limited
Notes to the financial statements
31 December 2025
Creditors
Finance income
Finance costs
Employee benefits
Share-based payments
The share-based payments are granted by a fellow group undertaking to employees of the Company based on the fair value of the equity instruments used. This fair value is determined at the grant date at a group level based on an appropriate valuation model taking into account the terms and conditions upon which the equity instruments were granted. The Company recognises the cost for the awards to the Company’s employees for their services rendered. The cost is recognised over the vesting period. At each reporting date prior to vesting, the vesting period and the number of awards expected to vest is estimated and the cumulative expense calculated. The movement in cumulative expense since the previous reporting date is in equity as there is no obligation for the Company to settle the share-based payments.
Fair value measurement
When an asset or liability, financial or non-financial, is measured at fair value for recognition or disclosure purposes, the fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date; and assumes that the transaction will take place either: in the principal market; or in the absence of a principal market, in the most advantageous market.
Fair value is measured using the assumptions that market participants would use when pricing the asset or liability, assuming they act in their economic best interests. For non-financial assets, the fair value measurement is based on its highest and best use. Valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, are used, maximising the use of relevant observable inputs and minimising the use of unobservable inputs.
20
ASE Corporate Eyecare Limited
Notes to the financial statements
31 December 2025
Leases
The company assesses whether a contract is or contains a lease, at inception of the contract. The company recognises a right-of-use asset and a corresponding lease liability with respect to all lease arrangements in which it is the lessee, except for short-term leases (defined as leases with a lease term of 12 months or less) and leases of low value assets (such as tablets and personal computers, small items of office furniture and telephones). For these leases, the company recognises the lease payments as an operating expense on a straight-line basis over the term of the lease unless another systematic basis is more representative of the time pattern in which economic benefits from the leased assets are consumed. The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted by using the rate implicit in the lease. If this rate cannot be readily determined, the lessee uses its incremental borrowing rate. Lease payments included in the measurement of the lease liability comprise:
|
• |
Fixed lease payments (including in-substance fixed payments), less any lease incentives receivable; |
|
|
• |
Variable lease payments that depend on an index or rate, initially measured using the index or rate at the commencement date; |
|
|
• |
The amount expected to be payable by the lessee under residual value guarantees; |
|
|
• |
The exercise price of purchase options, if the lessee is reasonably certain to exercise the options; and |
|
|
• |
Payments of penalties for terminating the lease, if the lease term reflects the exercise of an option to terminate the lease. |
The lease liability is presented as a separate line in the statement of financial position and is subsequently measured by increasing the carrying amount to reflect interest on the lease liability (using the effective interest method) and by reducing the carrying amount to reflect the lease payments made. The company remeasures the lease liability (and makes a corresponding adjustment to the related right-of-use asset) whenever:
|
• |
The lease term has changed or there is a significant event or change in circumstances resulting in a change in the assessment of exercise of a purchase option, in which case the lease liability is remeasured by discounting the revised lease payments using a revised discount rate. |
|
|
• |
The lease payments change due to changes in an index or rate or a change in expected payment under a guaranteed residual value, in which case the lease liability is remeasured by discounting the revised lease payments using an unchanged discount rate (unless the lease payments change is due to a change in a floating interest rate, in which case a revised discount rate is used). |
|
|
• |
A lease contract is modified and the lease modification is not accounted for as a separate lease, in which case the lease liability is remeasured based on the lease term of the modified lease by discounting the revised lease payments using a revised discount rate at the effective date of the modification. |
21
ASE Corporate Eyecare Limited
Notes to the financial statements
31 December 2025
The Company as a lessee (continued)
The company did not make any such adjustments during the periods presented.
The right-of-use assets comprise the initial measurement of the corresponding lease liability, lease payments made at or before the commencement day, less any lease incentives received and any initial direct costs. They are subsequently measured at cost less accumulated depreciation and impairment losses.
Whenever the company incurs an obligation for costs to dismantle and remove a leased asset, restore the site on which it is located or restore the underlying asset to the condition required by the terms and conditions of the lease, a provision is recognised and measured under IAS 37. To the extent that the costs relate to a right-of-use asset, the costs are included in the related right-of-use asset, unless those costs are incurred to produce inventories.
Right-of-use assets are depreciated over the shorter period of lease term and useful life of the underlying asset. If a lease transfers ownership of the underlying asset or the cost of the right-of-use asset reflects that the company expects to exercise a purchase option, the related right-of-use asset is depreciated over the useful life of the underlying asset.
The depreciation starts at the commencement date of the lease. As a practical expedient, IFRS 16 permits a lessee not to separate non-lease components, and instead account for any lease and associated non-lease components as a single arrangement. The company has not used this practical expedient. For a contract that contains a lease component and one or more additional lease or non-lease components, the company allocates the consideration in the contract to each lease component on the basis of the relative stand-alone price of the lease component and the aggregate stand-alone price of the non-lease components.
Called up share capital
Dividends
Note 3. Critical accounting judgements, estimates and assumptions
22
ASE Corporate Eyecare Limited
Notes to the financial statements
31 December 2025
Revenue recognition
- For Voucher-Based DSE Compliance Services the company acts as a principal as it controls the right to eye-care services by managing the service providers list, setting the prices for the service provided and managing the provision of those services. This results in ‘gross’ revenue recognition as described in the revenue recognition accounting policy - For Direct Settlement Administration Services and Platform and Network Management Services the company acts as an agent in exchange for a service fee as it does not control the transfer of goods or services by the retailer to the product holder upon redemption. This results in ‘net’ revenue recognition as described in the revenue recognition accounting policy
Deferred revenue
Note 4. Revenue
All of the company’s revenue, for the current and prior periods, is generated from within the United Kingdom and relates to the provision of corporate eye care and administration of a vaccination contract.
The Company’s operations are divided into two principal operating segments:
•
•
|
2025 |
2024 |
|||
|
£ |
£ |
|||
|
Principal revenue |
|
|
||
|
Agency revenue |
|
|
||
|
6,825,662 |
5,704,331 |
23
ASE Corporate Eyecare Limited
Notes to the financial statements
31 December 2025
Note 5. Operating profit
|
2025 |
2024 |
|||
|
£ |
£ |
|||
|
Operating profit is stated after charging: |
||||
|
Short term lease expense |
|
|
||
|
Audit fees payable to the company's auditor |
|
|
||
|
Depreciation |
|
|
||
|
Amortisation |
|
|
Note 6. Employees
The average monthly number of employees (including the directors) employed by the company during the year was as follows:
|
2025 |
2024 |
|||
|
Finance |
3 |
3 |
||
|
Customer services |
4 |
4 |
||
|
Sales |
5 |
5 |
||
|
Operations |
6 |
6 |
||
|
|
|
The employee benefits expense during the year was as follows:
|
2025 |
2024 |
|||
|
£ |
£ |
|||
|
Wages and salaries |
|
|
||
|
Social security costs |
|
|
||
|
Other pension costs |
|
|
||
|
Other share benefits |
|
|
||
|
Total employee benefits expense |
|
|
|
Directors' remuneration |
2025 |
2024 |
||
|
£ |
£ |
|||
|
Aggregate remuneration |
|
|
||
|
Pension contributions |
|
|
||
|
Share based payment |
|
|
||
|
186,410 |
166,579 |
Certain employees are members of the group share option scheme.
Note 7. Finance income
|
2025 |
2024 |
|||
|
£ |
£ |
|||
|
Interest on group loans |
|
|
24
ASE Corporate Eyecare Limited
Notes to the financial statements
31 December 2025
Note 8. Finance expense
|
2025 |
2024 |
|||
|
£ |
£ |
|||
|
Interest on group loans |
|
|
Note 9. Income tax (credit)/charge
|
2025 |
2024 |
|||
|
£ |
£ |
|||
|
Current tax: |
||||
|
UK Corporation tax on profits for the year |
|
|
||
|
Adjustment in respect of prior years |
( |
( |
||
|
Total current tax |
( |
|
||
|
Deferred tax: |
||||
|
Origination and reversal of timing differences - current year |
( |
|
||
|
Adjustments in respect of prior year |
|
|
||
|
( |
|
|||
|
Tax on profit on ordinary activities |
(31,246) |
90,416 |
Factors affecting the tax (credit)/charge for the year
The tax assessed for the year is lower than (2024: lower than) the effective rate of corporation tax as explained below:
|
2025 |
2024 |
|||
|
£ |
£ |
|||
|
Profit before income tax |
853,745 |
371,201 |
||
|
Tax at the statutory tax rate of 25% |
|
|
||
|
Effects of: |
||||
|
Fixed asset differences |
( |
|
||
|
Adjustments in respect of prior years - deferred tax |
|
|
||
|
Adjustments in respect of prior years - current tax |
( |
( |
||
|
Expenses not deductible |
( |
|
||
|
Other adjustments |
( |
( |
||
|
Income tax (credit)/charge |
(31,246) |
90,416 |
25
ASE Corporate Eyecare Limited
Notes to the financial statements
31 December 2025
Pillar Two income taxes
The European Union ("EU") Minimum Tax Directive (Council Directive 2022/2523) implemented in EU law the agreement reached in October 2021 by the Organisation for Economic Co-operation and Development ("OECD") in relation to the Global Anti-Base Erosion Model Rules ("Pillar Two"). These rules are intended to ensure that large multinational enterprise groups are subject to a minimum effective tax rate of 15% on a jurisdictional basis.
The Company's ultimate parent undertaking, EssilorLuxottica SA, is within the scope of the Pillar Two rules. The UK enacted Pillar Two legislation effective from 1 January 2024.
The Company has no current tax expense relating to Pillar Two taxes for the year ended 31 December 2025. In accordance with the amendments to FRS 101, the Company has applied the mandatory temporary exception from recognising and disclosing deferred tax assets and liabilities arising from Pillar Two income taxes.
Based on the Company's assessment, Pillar Two legislation is not expected to have a material impact on the Company's financial statements.
Note 10. Dividends
Dividends paid during the financial year were as follows:
|
2025 |
2024 |
|||
|
£ |
£ |
|||
|
Interim dividend for the year ended 31 December 2025 of £ |
|
- |
Note 11. Intangible assets
|
Computer software |
Website |
Total |
||||
|
£ |
£ |
£ |
||||
|
Cost |
||||||
|
At 1 January 2025 |
|
|
|
|||
|
Additions |
|
- |
|
|||
|
At 31 December 2025 |
|
|
|
|||
|
Accumulated amortisation |
||||||
|
At 1 January 2025 |
|
|
|
|||
|
Charge for the year |
|
|
|
|||
|
At 31 December 2025 |
|
|
|
|||
|
Net book value |
||||||
|
At 31 December 2025 |
166,337 |
8,198 |
174,535 |
|||
|
At 31 December 2024 |
209,344 |
16,397 |
225,741 |
26
ASE Corporate Eyecare Limited
Notes to the financial statements
31 December 2025
Note 12. Property, plant and equipment
|
Leased equipment |
Fixtures and fittings |
Computer equipment |
Total |
|||||
|
£ |
£ |
£ |
£ |
|||||
|
Cost |
||||||||
|
As at 1 January 2025 |
|
|
|
|
||||
|
Additions |
- |
|
|
|
||||
|
As at 31 December 2025 |
|
|
|
|
||||
|
Accumulated depreciation |
||||||||
|
As at 1 January 2025 |
|
|
|
|
||||
|
Charge for the year |
- |
|
|
|
||||
|
As at 31 December 2025 |
|
|
|
|
||||
|
Net book value |
||||||||
|
As at 31 December 2025 |
- |
32,344 |
29,922 |
62,266 |
||||
|
As at 31 December 2024 |
- |
32,062 |
33,123 |
65,185 |
There are no remaining liabilities shown in the balance sheet in respect of leased liabilities related to the right of use assets. The company previously leased IT equipment.
Note 13. Debtors
|
2025 |
2024 |
|||
|
£ |
£ |
|||
|
Current assets |
||||
|
Trade receivables |
|
|
||
|
Other receivables |
|
|
||
|
Prepayments |
|
|
||
|
Amounts owed by group companies |
|
|
||
|
Corporation tax recoverable |
|
- |
||
|
1,524,073 |
4,404,883 |
|||
|
2,465,318 |
5,334,156 |
The balance of the amounts owed by group companies includes a cash pooling facility with the parent company amounting to £1,210,496 (2024: £4,287,164). There is also £77,663 (2024: £99,417) which relates to outstanding intercompany debtors. Interest is paid at a commercial rate on the cash pooling facility. All group loans are unsecured and repayable on demand.
27
ASE Corporate Eyecare Limited
Notes to the financial statements
31 December 2025
Note 14. Creditors
|
2025 |
2024 |
|||
|
£ |
£ |
|||
|
Bank overdraft |
|
|
||
|
Trade payables |
|
|
||
|
Amounts due to group entities |
|
|
||
|
Corporation tax |
- |
|
||
|
Other tax and social security |
|
|
||
|
Accruals and deferred income |
|
|
||
|
Other payables |
|
- |
||
|
1,364,316 |
2,115,431 |
All amounts owed to group undertakings are under normal trade creditor terms and conditions, do not attract interest and are repayable on demand.
The bank overdraft is secured by Group as part of the Cash Pooling agreement.
Note 15. Deferred tax
|
2025 |
2024 |
|||
|
£ |
£ |
|||
|
Deferred tax liability |
|
|
The provision for deferred tax consists of the following deferred tax liabilities:
|
Accelerated capital allowances |
||
|
£ |
||
|
At 1 January 2025 |
8,914 |
|
|
Deferred tax credit to statement of comprehensive income for the period |
( |
|
|
At 31 December 2025 |
3,404 |
Note 16. Called up share capital
|
2025 |
2024 |
2025 |
2024 |
|||||
|
Shares |
Shares |
£ |
£ |
|||||
|
Ordinary shares - allotted, issued and fully paid |
|
|
|
|
Note 17. Reserves
Capital redemption reserve
The capital redemption reserve is a non-distributable reserve relating to the nominal value of shares repurchased.
28
ASE Corporate Eyecare Limited
Notes to the financial statements
31 December 2025
Share-based payments reserve
The reserve is used to recognise the value of equity benefits provided to employees and directors as part of their remuneration.
Retained profits
Retained profits are the cumulative profits and losses net of dividends paid. This reserve is distributable and reflects the amount available for future dividend distributions or reinvestment in the business.
Note 18. Commitments
No capital expenditure has been committed to but not incurred at the year end (2024: £Nil).
Note 19. Related party transactions
During the year the company made purchases from Graeme Hodges for £
The company is a wholly owned subsidiary of EssilorLuxottica S.A. and has taken advantage of the exemption conferred by the Financial Reporting Standard FRS 101 Reduced Disclosure Framework (FRS 101) not to disclose transactions with EssilorLuxottica S.A or its wholly owned subsidiaries.
Note 20. Ultimate controlling party
The ultimate parent undertaking, and controlling party, is
Note 21. Share-based payments
The cost of employees' services received in exchange for grant of rights under equity-based employee compensation schemes is measured at the fair value of the equity instruments granted and is expensed over the vesting period. The total amount to be expensed over the vesting period is determined by reference to the fair value of the equity instruments granted, excluding the impact of any non-market vesting conditions. Non-market vesting conditions are included in the assumptions about the number of equity instruments that are expected to become exercisable. At each balance sheet date, the company revises its estimates of the number of equity instruments that are expected to become exercisable. It recognizes the impact of the revision of original estimates, if any, in profit or loss with a corresponding adjustment to equity. The fair value is measured based on an appropriate valuation model taking into account the terms and conditions upon which the equity instruments were granted.
29
ASE Corporate Eyecare Limited
Notes to the financial statements
31 December 2025
Note 22. Events after the reporting period
The company entered into a lease that commenced on 1 January 2026 for an initial contractual term of three years. The lease includes an unconditional tenant-only break and an option exercisable by the Company after six months. A right of use asset and lease liability will be measured and recognised from the lease commencement date.
No other matter or circumstance has arisen since 31 December 2025 that has significantly affected, or may significantly affect the company's operations, the results of those operations, or the company's state of affairs in future financial years.